Impaired immunosuppressive role of myeloid-derived suppressor cells in acquired aplastic anemia

• Published in: Haematologica (Roma) 2022-12, Vol.107 (12), p.2834-2845
• Main Authors: Dong, Peiyuan, Chen, Lingyun, Wu, Hongfei, Huo, Jiali, Jiang, Zhongxing, Shao, Yingqi, Ren, Xiang, Huang, Jinbo, Li, Xingxin, Wang, Min, Nie, Neng, Zhang, Jing, Jin, Peng, Zheng, Yizhou, Ge, Meili
• Format: Article
• Language: English
• Subjects: Anemia, Aplastic - metabolism; Arginase - genetics; Bone Marrow Failure; Cell Differentiation; Humans; Immunosuppressive Agents; Myeloid-Derived Suppressor Cells - metabolism; Sirolimus - pharmacology
• ISSN: 0390-6078; 1592-8721
• DOI: 10.3324/haematol.2021.280292

Myeloid-derived suppressor cells (MDSC) are a group of heterogeneous immature myeloid cells and display immunosuppressive function. In this study, MDSC populations were evaluated in acquired aplastic anemia (AA) (n=65) in which aberrant immune mechanisms contributed to bone marrow destruction. Our data demonstrate that both the proportion and immunosuppressive function of MDSC are impaired in AA patients. Decreased percentage of MDSC, especially monocytic MDSC, in the blood of AA patients (n=15) is positively correlated with the frequency of T-regulatory cells, bone marrow level of WT1 and decreased plasma level of arginase-1. RNA sequencing analyses reveal that multiple pathways including DNA damage, interleukin 4, apoptosis, and Jak kinase singnal transducer and activator of transcription are upregulated, whereas transcription, IL-6, IL-18, glycolysis, transforming growth factor and reactive oxygen species are downregulated in MDSC of AA (n=4), compared with that of healthy donors (n=3). These data suggest that AA MDSC are defective. Administration of rapamycin significantly increases the absolute number of MDSC and levels of intracellular enzymes, including arginase-1 and inducible nitric-oxide synthase. Moreover, rapamycin inhibits MDSC from differentiating into mature myeloid cells. These findings reveal that impaired MDSC are involved in the immunopathogenesis of AA. Pharmacologically targeting of MDSC by rapamycin might provide a promising therapeutic strategy for AA.